Social costs of robbery and the cost-effectiveness of substance abuse treatment

Health Economics

Volumn 17, Issue 8, 2008, Pages 927-946

  Basu, Anirban ^a   Paltiel, A David ^b   Pollack, Harold A ^c  

^a UNIVERSITY OF CHICAGO   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c The University of Chicago   (United States)

Author keywords

Contingent valuation; Cost benefit; Drug treatment; Robbery; Substance abuse

Indexed keywords

METHADONE;

ADULT; AMBULATORY CARE; ARTICLE; BINOMIAL DISTRIBUTION; CONTINGENT VALUATION; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; CRIME; DRUG DEPENDENCE; ECONOMIC ASPECT; FEMALE; HEALTH CARE COST; HUMAN; INCIDENCE; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MALE; OFFENDER; OUTPATIENT CARE; PRETEST POSTTEST DESIGN; PRIORITY JOURNAL; REGRESSION ANALYSIS; RISK REDUCTION; SELF REPORT; SOCIAL ASPECT; STATISTICAL SIGNIFICANCE; SUBSTANCE ABUSE;

ADOLESCENT; ADULT; COHORT STUDIES; COST-BENEFIT ANALYSIS; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; SUBSTANCE ABUSE TREATMENT CENTERS; SUBSTANCE-RELATED DISORDERS; THEFT;

EID: 50249096700     PISSN: 10579230     EISSN: 10991050     Source Type: Journal    
DOI: 10.1002/hec.1305     Document Type: Article

References (49)

1. Allen C. 2005. The links between heroin, crack cocaine, and crime. British Journal of Criminology 45: 355-372.
2. Barnett P. 1999. The cost-effectiveness of methadone maintenance as a health care intervention. Addiction 94(4): 479-488.
3. Barnett P, Swindle R. 1997. Cost-effectiveness of inpatient substance abuse treatment. Health Services Research 32(5): 615-629.
4. Blumstein A, Cohen J. 1987. Characterizing criminal careers. Science 237(4818): 985-991.
5. Cameron A, Trivedi P. 1998. Regression Analysis of Count Data. Cambridge University Press: Cambridge, UK.
6. Cartwright W. 1998. Cost-benefit and cost-effectiveness analysis of drug abuse treatment services. Evaluation Review 2(5): 609-636.
7. Cartwright W. 2000. Cost-benefit analysis of drug treatment services: review of the literature. Journal of Mental Health Policy and Economics 3(1): 11-26.
8. Caulkins J. 1997. Mandatory Minimum Drug Sentences: Throwing Away the Key or the Taxpayers' Money? RAND Drug Policy Research Center: Santa Monica.
9. Chamberlain G. 1980. Analysis of covariance with qualitative data. Review of Economic Studies 47: 225-238.
10. Cohen M, Rust R et al. 2004. Willingness to pay for crime control programs. Criminology 42(1): 89-110.
11. Dismuke C, French M et al. 2004. Out of touch or on the money: do the clinical objectives of addiction treatment coincide with economic evaluation results? Journal of Substance Abuse Treatment 27: 253-263.
12. Donahue J, Siegelman P. 1998. Allocating resources among prisons and social programs in the battle against crime. Journal of Legal Studies 27: 1-43.
13. Flynn P, Kristiansen P et al. 1999. Costs and benefits of treatment for cocaine addiction in DATOS. Drug and Alcohol Dependence 57(2): 167-174.
14. Flynn P, Simpson D et al. 2001. Comment on nonresponse and selection bias in treatment follow-up studies. Substance Use and Misuse 36(12): 1753-1757.
15. French M, Dunlap L et al. 1997. A structured instrument for estimating the economic cost of drug abuse treatment. Journal of Substance Abuse Treatment 14(5): 445-455.
16. French M, McGeary K. 1997. Estimating the economic cost of substance abuse treatment. Health Economics 6: 539-544.
17. French M, Salomé J et al. 2002. Benefit-cost analysis of addiction treatment: methodological guidelines and empirical application using the DATCAP and ASI. Health Services Research 37(2): 433-455.
18. Friedmann P, Alexander J et al. 1999. Organizational correlates of access to primary care and mental health services in drug abuse treatment units. Journal of Substance Abuse Treatment 16(1): 71-80.
19. Gerstein D, Johnson R. 2000. Nonresponse and selection bias in treatment follow-up studies. Substance Use and Misuse 35(6-8): 971-1014.
20. Gerstein D, Johnson R. 2001. In reply to Patrick M. Flynn and colleagues. Substance Use and Misuse 36(12): 1753-1757.
21. Gerstein DR, Datta AR et al. 1997. NTIES Final Report. National Opinion Research Center, Chicago, IL.
22. Gerstein DR, Harwood HJ. 1990. Treating Drug Problems. National Academy Press, Institute of Medicine: Washington, DC.
23. Harwood H, Fountain D et al. 1999. Cost estimates for alcohol and drug abuse. A Report and Commentaries. Addiction 94(5): 631-647.
24. Hausman J, Hall B et al. 1984. Econometric models for count data with an application to the patents-R and D relationship. Econometrica 52: 909-938.
25. IOM 2000. No Time to Lose: Making the most of HIV Prevention. National Academy Press: Washington, DC.
26. Johnson B, Goldstein P et al. 1985. Taking Care of Business: The Economics of Crime by Heroin Users. Lexington Books: Lexington, MA.
27. Kleiman M. 1993. Against Excess: Drug Policy for Results. Basic Books: New York.
28. Magura S, Nwakeze PC et al. 1998. Pre- and in-treatment predictors of retention in methadone treatment using survival analysis. Addiction 93(1): 51-60.
29. Massing M. 1998. The Fix. Simon & Schuster: New York, NY.
30. McCollister K, French M. 2003. The relative contribution of outcome domains in the total economic benefit of addiction interventions: a review of first findings. Addiction 98: 1647-1659.
31. McGlothlin WH, Anglin MD. 1981. Shutting off methadone. Costs and benefits. Archives of General Psychiatry 38(8): 885-892.
32. McLellan A, Grissom G et al. 1997. Problem-service 'Matching' in addiction treatment. Archives of General Psychiatry 54(8): 730-735.
33. McLellan A, Woody G et al. 1997. Evaluating the effectiveness of addiction treatment: reasonable expectations, appropriate comparisons. In Treating Drug Abusers Effectively, Egertson J, Fox D, Leshner A (eds). Blackwell: Oxford, 7-40.
34. Metzger D, Woody G et al. 1993. Human immunodeficiency virus seroconversion among intravenous drug users in- and out-of-treatment: an 18-month prospective follow-up. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 6(9): 1049-1056.
35. Mojtabai R, Zivin J. 2003. Effectiveness and cost-effectiveness of four treatment modalities for substance disorders: a propensity score analysis. Health Services Research 38(1): 233-259.
36. Nagin DS, Piquero AR et al. 2006. Public preferences for rehabilitation versus incarceration of juvenile offenders: evidence from a contingent valuation survey. Criminology & Public Policy 5(4): 627-651.
37. Neyman J, Scott E. 1948. Consistent estimates based on partially consistent observations. Econometrica 16:1-32.
38. Pollack H. 2002. Methadone treatment as HIV prevention: cost-effectiveness analysis. In Quantitative Evaluation of HIV Prevention Programs, Kaplan EH, Brookmeyer R (eds). Yale University Press: New Haven, CT, 118-143.
39. Pollack H, Khoshnood K et al. 2002. The impact of needle exchange-based health services on emergency department use. Journal of General Internal Medicine 17(5): 341-348.
40. Rajkumar A, French M. 1997. Drug abuse, crime costs, and the economic benefits of treatment. Journal of Quantitative Criminology 13(3): 291-322.
41. Roebuck M, French M et al. 2003. DATStats: results from 85 studies using the Drug Abuse Treatment Cost Analysis Program (DATCAP). Journal of Substance Abuse Treatment 25: 51-57.
42. Schwartz R, Highfield D et al. 2006. A randomized controlled trial of interim methadone maintenance. Archives of General Psychiatry 63(1): 102-109.
43. Shepard D, Larson M et al. 1999. Cost-effectiveness of substance abuse services. The Psychiatric Clinics of North America 22(2): 385-400.
44. Sindelar J, Fiellin D. 2001. Innovations in treatment for drug abuse: solutions to a public health problem. Annual Review of Public Health 22: 249-272.
45. Sindelar J, Jofre-Bonet M et al. 2064. Cost-effectiveness analysis of addiction treatment: paradoxes of multiple outcomes. Drug and Alcohol Dependence 73: 41-50.
46. Wheeler J, Fadel H et al. 1992. Ownership and performance of outpatient substance abuse treatment centers. American Journal of Public Health 82(5): 711-718.
47. Wooldridge J. 2002. Econometric Analysis of Cross-Section and Panel Data. MIT Press: Cambridge, MA.
48. Zaric G, Brandeau M et al. 2000. Methadone maintenance and HIV prevention: a cost-effectiveness analysis. American Journal of Public Health 90(7): 1-12.
49. Zarkin G, Dunlap L et al. 2002. The effect of treatment completion and length of stay on employment and crime in outpatient drug-free treatment. Journal of Substance Abuse Treatment 23(4): 261-267.